FDA-approved TIVDAK®: Targeting tissue factor in cervical cancer

FHS
May 10, 2024
11:51 am

On April 29th, 2024, the U.S. FDA granted full approval for Seagen Inc.’s TIVDAK® (tisotumab vedotin) targeting tissue factor (TF) for the treatment of patients with recurrent or metastatic cervical cancer who have progressed on or after chemotherapy. This marks a significant advancement in the therapeutic landscape for cervical cancer, highlighting the potential of antibody-drug conjugates (ADCs) in oncology.

BetterLife Continues Progress on BETR-001 IND-Enabling Studies | Psychedelic Invest

BetterLife Pharma Inc. (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, today announced that the

June 9, 2023

Bayer’s new CEO was dealt a duo of ‘clearing events.’ Tough choices lie ahead

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, everyone. Damian

November 21, 2023

Biogen shareholders elect biotech exec Susan Langer to the board after romantic partner departs

Biogen shareholders have elected Susan Langer to the drugmaker’s board, part of a series of changes to refresh the biotech’s governance. Langer’s nomination to the

June 27, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.